[Analysis of the expression of the antigen recognized by monoclonal antibody MSN-1 in endometrial hyperplasia which progressed to endometrial cancer]. 1992

K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo.

UI MeSH Term Description Entries
D004714 Endometrial Hyperplasia Benign proliferation of the ENDOMETRIUM in the UTERUS. Endometrial hyperplasia is classified by its cytology and glandular tissue. There are simple, complex (adenomatous without atypia), and atypical hyperplasia representing also the ascending risk of becoming malignant. Atypical Endometrial Hyperplasia,Complex Endometrial Hyperplasia,Simple Endometrial Hyperplasia,Atypical Endometrial Hyperplasias,Complex Endometrial Hyperplasias,Endometrial Hyperplasia, Atypical,Endometrial Hyperplasia, Complex,Endometrial Hyperplasia, Simple,Endometrial Hyperplasias,Endometrial Hyperplasias, Atypical,Endometrial Hyperplasias, Complex,Endometrial Hyperplasias, Simple,Hyperplasia, Atypical Endometrial,Hyperplasia, Complex Endometrial,Hyperplasia, Endometrial,Hyperplasia, Simple Endometrial,Hyperplasias, Atypical Endometrial,Hyperplasias, Complex Endometrial,Hyperplasias, Endometrial,Hyperplasias, Simple Endometrial,Simple Endometrial Hyperplasias
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D013194 Staining and Labeling The marking of biological material with a dye or other reagent for the purpose of identifying and quantitating components of tissues, cells or their extracts. Histological Labeling,Staining,Histological Labelings,Labeling and Staining,Labeling, Histological,Labelings, Histological,Stainings
D014594 Uterine Neoplasms Tumors or cancer of the UTERUS. Cancer of Uterus,Uterine Cancer,Cancer of the Uterus,Neoplasms, Uterine,Neoplasms, Uterus,Uterus Cancer,Uterus Neoplasms,Cancer, Uterine,Cancer, Uterus,Cancers, Uterine,Cancers, Uterus,Neoplasm, Uterine,Neoplasm, Uterus,Uterine Cancers,Uterine Neoplasm,Uterus Cancers,Uterus Neoplasm

Related Publications

K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
February 1995, Nihon Sanka Fujinka Gakkai zasshi,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
January 1997, Oncology reports,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
May 1998, Japanese journal of cancer research : Gann,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
January 1992, Urologia internationalis,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
November 1988, Cancer biochemistry biophysics,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
January 1997, Journal of periodontal research,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
February 1996, Experimental hematology,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
October 1992, Nihon rinsho. Japanese journal of clinical medicine,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
December 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
K Tsukazaki, and Y Kobayashi, and N Yoshida, and M Sakayori, and S Nozawa
January 1992, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!